BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26352389)

  • 21. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
    J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
    Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
    Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
    Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
    Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
    Vanni I; Coco S; Truini A; Rusmini M; Dal Bello MG; Alama A; Banelli B; Mora M; Rijavec E; Barletta G; Genova C; Biello F; Maggioni C; Grossi F
    Int J Mol Sci; 2015 Dec; 16(12):28765-82. PubMed ID: 26633390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer.
    Skronski M; Chorostowska-Wynimko J; Szczepulska E; Szpechcinski A; Rudzinski P; Orlowski T; Langfort R
    Adv Exp Med Biol; 2013; 756():321-31. PubMed ID: 22836650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
    Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
    Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
    Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
    Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.
    Khode R; Larsen DA; Culbreath BC; Parrish S; Walker KL; Sayage-Rabie L; Beissner RS; Rao A
    Cancer Cytopathol; 2013 Jul; 121(7):361-9. PubMed ID: 23364874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples.
    Hlinkova K; Babal P; Berzinec P; Majer I; Mikle-Barathova Z; Piackova B; Ilencikova D
    Diagn Mol Pathol; 2013 Jun; 22(2):70-5. PubMed ID: 23628817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer.
    Sriram KB; Tan ME; Savarimuthu SM; Wright CM; Relan V; Stockwell RE; Clarke BE; Duhig EE; Yang IA; Bowman RV; Fong KM
    Eur Respir J; 2011 Oct; 38(4):903-10. PubMed ID: 21349912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR Mutational Profiling in Non-Small Cell Lung Cancer: The Clinical Performance of a Sensitive Reverse-Hybridization Assay.
    Kriegshäuser G; Enko D; Novy M; Reitmayr A; Loidl A; Halwachs-Baumann G; Oberkanins C
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):388-392. PubMed ID: 27801728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
    Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
    Cernomaz AT; Macovei II; Pavel I; Grigoriu C; Marinca M; Baty F; Peter S; Zonda R; Brutsche M; Grigoriu B
    BMC Pulm Med; 2016 May; 16(1):88. PubMed ID: 27215400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].
    Zhang HP; Ruan L; Zheng LM; Bai DY; Zhang HF; Liao YQ; Ding Y
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):28-32. PubMed ID: 23648296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
    Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
    Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.
    Yatabe Y; Kerr KM; Utomo A; Rajadurai P; Tran VK; Du X; Chou TY; Enriquez ML; Lee GK; Iqbal J; Shuangshoti S; Chung JH; Hagiwara K; Liang Z; Normanno N; Park K; Toyooka S; Tsai CM; Waring P; Zhang L; McCormack R; Ratcliffe M; Itoh Y; Sugeno M; Mok T
    J Thorac Oncol; 2015 Mar; 10(3):438-45. PubMed ID: 25376513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.